Concepedia

A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies

Howard A. Burris, Charles W. Taylor, Suzanne F. Jones, Kevin M. Koch, M. Versola, Niki Arya, Ronald A. Fleming, Deborah A. Smith, Lini Pandite, Neil L. Spector,

Clinical Cancer Research · 2009 · 95 citations · 24 references

DOIFull text

Open access

Abstract

Lapatinib was well tolerated following once and twice daily administration. Systemic exposure to lapatinib was dependent on the dose, duration and frequency of dosing, and prandial state. Clinical activity was observed.

References

24

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

, , +17

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/<i>neu</i>Oncogene

Dennis J. Slamon, Gary M. Clark, Steven Wong et al. · Science · 1987 · 11.6K citations

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

Melody Cobleigh, Charles L. Vogel, Debu Tripathy et al. · Journal of Clinical Oncology · 1999 · 2.8K citations

Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival

Jennifer R. Grandis, Mona F. Melhem, William E. Gooding et al. · JNCI Journal of the National Cancer Institute · 1998 · 1.1K citations · Full text

Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin

José Baselga, David G. Pfister, Michael R. Cooper et al. · Journal of Clinical Oncology · 2000 · 743 citations